SCHEMBL91443

SCHEMBL91443

Cc1ccnc2[nH]ccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 5/20 0.59
AXL P30530 2/20 0.59
AURKB Q96GD4 3/20 0.52
ROCK1 Q13464 2/20 0.52
JAK2 O60674 2/20 0.52
JAK3 P52333 2/20 0.52
IKBKB O14920 1/20 0.52
CHUK O15111 1/20 0.52
DAPK3 O43293 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PAK4 O96013 1/20 0.52
CSF1R P07333 1/20 0.52
RET P07949 1/20 0.52
IGF1R P08069 1/20 0.52
FGFR1 P11362 1/20 0.52
PRKACA P17612 1/20 0.52
FLT1 P17948 1/20 0.52
LTK P29376 1/20 0.52
GRK5 P34947 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30669881 0.82 PRKCI (0.49) PRKCIAXLAURKBROCK1JAK2
SCHEMBL13778254 0.79 CCR1 (0.43) PRKCIAXLAURKBROCK1JAK2
SCHEMBL12127530 0.79 NUDT1 (0.65) PRKCIAURKBROCK1JAK2JAK3
SCHEMBL2240671 0.77 AURKB (0.71) PRKCIAXLAURKBROCK1JAK2
SCHEMBL12127277 0.76 IKBKB (0.58) PRKCIAXLAURKBROCK1JAK2
SCHEMBL10080580 0.76 AURKB (0.63) PRKCIAURKBROCK1JAK2JAK3
SCHEMBL1328236 0.75 NUDT1 (0.46) PRKCIAXLAURKBROCK1JAK2
SCHEMBL3093132 0.75 PRKCI (0.55) PRKCIAXLAURKBROCK1JAK2
SCHEMBL14494236 0.75 NUDT1 (0.54) PRKCIAURKBROCK1JAK2JAK3
SCHEMBL3339974 0.74 PRKCI (0.59) PRKCIAXLAURKBROCK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294522-A1 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS LEAD DISCOVERY CENTER GMBH (DE) 2024-09-05 US claimed
US-20130059850-A1 AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH MERCK SHARP & DOHME CORP. (US) 2013-03-07 US claimed
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 US disclosed
US-20250361233-A1 Compounds For Activating Serotonin Receptor Psylo Pty Ltd (AU) 2025-11-27 US disclosed
US-20250340549-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, AND COMPOSITIONS AND USES THEREOF HARVARD COLLEGE (US) 2025-11-06 US disclosed
US-12415804-B2 Compounds for activating a serotonin receptor Psylo Pty Ltd (AU) 2025-09-16 US disclosed
US-20250206739-A1 Compounds Psylo Pty Ltd (AU) 2025-06-26 US disclosed
US-20250163044-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-05-22 US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 EP disclosed
CN-118974044-A Compounds of formula (I) 赛洛私人有限公司 2024-11-15 CN disclosed
EP-4452979-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 EP disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO disclosed
US-20070066641-A1 Compounds and methods for development of RET modulators PLEXXIKON, INC. 2007-03-22 US disclosed
US-20070049615-A1 Compounds and methods for development of Ret modulators PLEXXIKON, INC. 2007-03-01 US disclosed
US-20070049615-A1 Compounds and methods for development of Ret modulators PLEXXIKON, INC. 2007-03-01 US disclosed
WO-2007022501-A2 USEFUL INDOLE COMPOUNDS MICROBIA, INC. (US) 2007-02-22 WO disclosed
WO-2007006547-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
US-20060058304-A1 Azaindole kinase inhibitors BHIDE RAJEEV S 2006-03-16 US disclosed
US-6969717-B2 Azaindole kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-29 US disclosed
WO-2005058891-A1 PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206739-A1 Compounds NLN, SLC18A2, PYGB PRKCI 3462/4885AXL 4487/4885AURKB 2276/4885
US-20250340549-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, AND COMPOSITIONS AND USES THEREOF NNMT, NAMPT, NNT PRKCI 4332/4885AXL 3921/4885AURKB 1396/4885
US-12415804-B2 Compounds for activating a serotonin receptor HTR2C, HTR6, HTR2A PRKCI 2697/4885AXL 2597/4885AURKB 2450/4885
US-20130059850-A1 AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH FAAH, FAAH2, IDO1 PRKCI 2309/4885AXL 4355/4885AURKB 2053/4885
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 PRKCI 88/4885AXL 2763/4885AURKB 237/4885
US-20250361233-A1 Compounds For Activating Serotonin Receptor HTR2C, HTR2A, HTR6 PRKCI 2973/4885AXL 2342/4885AURKB 2529/4885
US-20070066641-A1 Compounds and methods for development of RET modulators RET, FGFR1, FGFR3 PRKCI 1690/4885AXL 21/4885AURKB 625/4885
US-20240294522-A1 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS GRK5, GRK3, GRK4 PRKCI 1537/4885AXL 2226/4885AURKB 1321/4885
US-20250163044-A1 COMPOUNDS NLN, SLC18A2, PYGB PRKCI 3462/4885AXL 4487/4885AURKB 2276/4885
US-20060058304-A1 Azaindole kinase inhibitors FGFR1, FGFR2, FLT1 PRKCI 754/4885AXL 82/4885AURKB 112/4885
US-20070049615-A1 Compounds and methods for development of Ret modulators RET, GFRA1, GFRA3 PRKCI 1792/4885AXL 73/4885AURKB 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.